mRNA vaccine is plug and play once you decide on which antigen you want for vaccine. Just create the new mRNA sequence and it goes into the platform tech. First drug of platform is toughest to get started then others much easier. NNVC hopefully will go much quicker on second and third drug if using same nanomicelle backbone .. Just design and synthesize new ligand and attachment method and have a new drug.
Agree though NNVC with never getting into trials yet is very bad. Probably due to manufacturing or CMC issues? Looks like they are close to IND though for real this time, definitely maybe perhaps will see.
Market Data 
Markets 
AI
